GlassScriptPhysician profile
Ashley C Walsh
NPI 1689808180
$2,237.29
in general payments reported to CMS, 2019-2025
20 companies · $61.28 in 2025
The $61.28 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $196 · 2020: $108 · 2021: $126 · 2022: $74.64 · 2023: $1,516 · 2024: $155 · 2025: $61.28.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,500 · Food and Beverage: $232.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,500.00 |
| Food and Beverage | $232.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Palette Life Sciences, INC. | $1,500.00 | 2023 | |
| Abbvie INC. | $140.91 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $99.18 | 2019-2022 | |
| Astellas Pharma US INC | $78.53 | 2019-2024 | Veozah |
| Sage Therapeutics, LLC | $72.63 | 2024 | |
| Organon LLC | $64.71 | 2022-2025 | Nexplanon |
| Mayne Pharma Commercial LLC | $33.72 | 2025 | |
| Boston Scientific Corporation | $31.02 | 2019 | |
| Avion Pharmaceuticals | $30.37 | 2019 | |
| Ethicon US, LLC | $30.17 | 2021 | |
| Edwards Lifesciences Corporation | $24.94 | 2024 | Hemosphere |
| Hologic Sales and Service, LLC | $22.68 | 2024 | Acessa Provu System |
| Scynexis, INC. | $19.21 | 2022 | |
| Allergan, INC. | $17.01 | 2019 | |
| Coopersurgical, INC. | $15.88 | 2023 | Summit Doppler |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $15.22 | 2025 | Myfembree |
| Myovant Sciences INC. | $13.97 | 2021 | |
| Therapeuticsmd, INC. | $13.75 | 2020 | |
| Merck Sharp & Dohme LLC | $13.39 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Walsh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.